Tempest Therapeutics, Inc. (TPST): Marketing Mix Analysis [Apr-2026 Updated]

You're looking at Tempest Therapeutics, Inc. (TPST) right now, and honestly, for a clinical-stage biotech, the marketing mix isn't about sales yet; it's about proving pipeline value to secure a strategic partner. As of late 2025, the entire commercial reality-from the Phase 3-ready Amezalpat (TPST-1120) to the fact that current product revenue is a hard $0-is laser-focused on one thing: translating scientific milestones into a deal that funds the next step. I've broken down the Product, Place, Promotion, and Price below, showing exactly how this high-stakes, pre-commercial environment defines every move Tempest Therapeutics, Inc. (TPST) is making.

Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Product

You're looking at the core offering of Tempest Therapeutics, Inc. (TPST) as of late 2025. The product element here is entirely focused on novel, first-in-class oncology therapeutics designed to either kill tumor cells directly, activate the immune system, or both. The pipeline is anchored by two small molecule candidates and recently expanded by a significant CAR-T acquisition.

The primary asset driving near-term value is Amezalpat (TPST-1120), a first-in-class oral antagonist selective for peroxisome proliferator-activated receptor alpha (PPAR$\alpha$). This compound is being developed for first-line Hepatocellular Carcinoma (HCC). The core value proposition stems from Phase 1b/2 data showing a six-month improvement in median overall survival (OS) when used in combination with atezolizumab and bevacizumab, compared to the standard of care (SOC) doublet alone. Specifically, the median OS reached 21 months for the triplet arm versus 15 months for the control arm, yielding a hazard ratio (HR) of 0.65. Furthermore, 50% (20/40) of patients in the active arm remained in survival follow-up at the last data cutoff. Tempest Therapeutics is preparing for a pivotal Phase 3 study, which is planned to enroll over 700 patients, aiming to replicate this efficacy and safety profile on a larger scale. The potential market for this regimen in the US and five major European markets is estimated at over 28,000 first-line patients.

TPST-1120 has secured important regulatory recognition from the U.S. Food and Drug Administration (FDA), holding both Orphan Drug and Fast Track designations for HCC, which helps streamline development and potential market access.

The second clinical-stage asset is TPST-1495, a potential orally bioavailable first-in-class EP2/4 dual antagonist. This program targets Familial Adenomatous Polyposis (FAP), a rare, inherited syndrome affecting approximately 1 in 5,000 to 10,000 individuals in the US, for which there are currently no approved medical therapies. TPST-1495 also received Orphan Drug Designation (ODD) from the FDA. A Phase 2 study, conducted by the Cancer Prevention Clinical Trials Network and funded by the National Cancer Institute (NCI), was set to start in 2025, with results anticipated in 2026.

In a move to diversify the pipeline, Tempest Therapeutics announced in November 2025 the definitive agreements to acquire the TPST-2003 program. This new asset is a clinical-stage CD19/BCMA dual-CAR-T program specifically designed to target patients with extramedullary disease. The transaction, structured as an all-stock deal expected to close in early 2026, involves issuing 8,268,495 shares of common stock, which represented 65% of outstanding shares as of November 19, 2025. Phase 1 trials in relapsed multiple myeloma patients have been completed, with data expected in 2026. This acquisition, coupled with an investment commitment from the seller, is projected to extend Tempest Therapeutics' operational runway to mid-2027.

Here's a quick look at the key product candidates as of late 2025:

The product strategy centers on leveraging specific molecular targets to achieve clinical superiority over existing regimens, as demonstrated by the OS data for TPST-1120. The company's product focus includes:

• Targeting tumor cell energy production via PPAR$\alpha$ inhibition.
• Modulating the immune suppressive tumor microenvironment.
• Developing dual-receptor antagonists for signaling pathways like PGE2.
• Expanding into cell therapy with the dual-targeting CAR-T platform.

As of the November 2025 acquisition announcement, Tempest Therapeutics' market capitalization was approximately $41.03 million.

Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Place

You're looking at the distribution strategy for Tempest Therapeutics, Inc. (TPST) right now, and honestly, it's not about shelves in retail stores or warehouse logistics yet. As of late 2025, the 'Place' is strictly defined by where their investigational products can be tested.

Tempest Therapeutics, Inc. currently operates with no commercial distribution network in place. The entire focus for 'Place' is virtual, centered entirely on identifying and managing appropriate clinical sites for ongoing and planned trials. This is typical for a clinical-stage biotech, but the financial reality makes the next step critical.

The company ended the third quarter of 2025 with $7.5 million in cash and cash equivalents, a significant drop from the $30.3 million held on December 31, 2024. With a net loss of $3.5 million reported for Q3 2025, this cash position underscores why the distribution strategy is entirely contingent on external forces.

The current clinical footprint for the lead asset, amezalpat (TPST-1120), is decidedly global, reflecting the need for broad patient access to support a registration-directed trial. You need to know that the pivotal Phase 3 study has secured clearance across key markets:

• U.S. (FDA clearance received for the TPST-1120-301 study).
• Europe (Agreement with the EMA on the Phase 3 study design).
• China (Approval received from the National Medical Products Administration (NMPA) to proceed).

This global reach is essential because the ultimate commercial distribution strategy for both pipeline assets is contingent on a strategic partnership or acquisition. Tempest is actively exploring alternatives, including mergers, acquisitions, or licensing arrangements, to secure the resources needed for late-stage development and subsequent market access. The exploration of these strategic alternatives is a direct function of the current capital environment.

For the second program, TPST-1495, the distribution of the drug is managed entirely through a specialized academic network. The Phase 2 trial for Familial Adenomatous Polyposis (FAP) is being run through the NCI's Cancer Prevention Clinical Trials Network. This arrangement is financially de-risked for Tempest, as the trial is funded by the National Cancer Institute (NCI) Division of Cancer Prevention, with data expected in 2026.

For the planned Phase 3 trial of TPST-1120 in first-line Hepatocellular Carcinoma (HCC), the supply chain for one key component is already established through an existing collaboration with Roche. This partnership, formalized in October 2024, ensures the necessary drug supply for the pivotal study:

The clinical trial infrastructure for TPST-1120 is set up to be a global, randomized study, comparing amezalpat plus the Roche/Genentech standard of care against the standard of care alone. The agreement with Roche covers the supply for this pivotal testing phase, which is the current mechanism for 'placing' the drug with patients.

Finance: draft 13-week cash view by Friday.

Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Promotion

For Tempest Therapeutics, Inc. (TPST), promotion is heavily weighted toward scientific credibility and strategic financial positioning, given its clinical-stage focus. You're hiring before product-market fit, so the market validation comes from data and the ability to fund the next step.

Scientific Validation and Conference Presence

The primary promotional activity centers on presenting scientific validation at key industry events. Tempest Therapeutics reported new data supporting the immune component of amezalpat's (TPST-1120) dual mechanism of action at the 2025 AACR Annual Meeting, which took place April 25-30, 2025, in Chicago, IL. Specifically, a poster presentation detailing the mechanism of action occurred on Monday, April 28, 2025, between 9:00 a.m. - 12:00 p.m. CT. This data reinforced the potential of amezalpat as a novel cancer treatment by showing it reduced tumor-promoting immunosuppression.

Key promotional milestones presented include:

• Amezalpat (TPST-1120) data presented at 2025 AACR.
• Planned start for the global randomized Phase 3 study (NCT06680258) estimated for December 2025.
• Positive randomized Phase 1b/2 data showing clinical superiority over standard of care.
• FDA clearance to proceed with the pivotal trial of amezalpat combination therapy in China (received by August 2025).

Key Messaging and Product Potential

The core message promoted around the lead candidate, amezalpat (TPST-1120), centers on its 'blockbuster potential' specifically in first-line Hepatocellular Carcinoma (HCC). This potential is underpinned by regulatory achievements and clinical trial results.

The drug is positioned as an oral, small molecule, selective PPAR$\alpha$ antagonist.

Strategic Alternatives and Funding Narrative

A significant part of the late-2025 promotional narrative to investors involves the active pursuit of strategic alternatives, necessitated by funding gaps for the upcoming Phase 3 trial. Tempest Therapeutics announced in April 2025 that it was exploring options including mergers, acquisitions, partnerships, joint ventures, and licensing agreements. The company retained MTS Health Partners, L.P., as its financial advisor for this process. This move was explicitly linked to the capital markets being 'unavailable' to support the next stage of advancement after ending 2024 with just over $30 million in cash and equivalents, which was insufficient for a full Phase 3 funding.

Investor Relations and Cash Runway Management

Investor relations communications focus on pipeline advancement coupled with efforts to extend the cash runway. A major development in November 2025 was the announcement of a Strategic Acquisition of New Dual-CAR T Programs from Factor, which included a Simultaneous Runway Extension Projected to Mid-2027. This was supported by a financing event, specifically a Registered Direct Offering of up to $8.35 Million announced in November 2025.

The financial reality driving this communication is evident in the cash balances reported:

• Cash and cash equivalents as of December 31, 2024: $30.3 million.
• Cash and cash equivalents as of March 31, 2025 (Q1): $21.5 million.
• Cash and cash equivalents as of September 30, 2025 (Q3): $7.5 million.

The net loss for the three months ended March 31, 2025, was $10.9 million, or $3.16 per share (adjusted for the reverse split). The Q3 2025 net loss was reported as $3.5 million. The narrative emphasizes that despite these cash burn rates, the pipeline progress, including the runway extension to mid-2027, is a key focus for current stakeholders.

Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Price

You're looking at the pricing component for Tempest Therapeutics, Inc. (TPST) right now, and the reality is stark: the immediate price of the product is currently zero because the company is pre-revenue.

Current product revenue is $0, as Wall Street analysts forecast for 2025. This lack of commercial revenue means the financial 'price' you are dealing with is defined by the burn rate and the capital required to reach a commercial inflection point.

The company's financial price is defined by its net loss of $22.2 million for the nine months ended September 30, 2025. This figure, alongside cash usage, dictates the timeline for any strategic move, which directly impacts negotiation leverage on price.

Here's a quick look at the financial context driving the pricing strategy:

Future product pricing will target a premium oncology price point due to Orphan Drug status. This designation, received for candidates like TPST-1495 for Familial Adenomatous Polyposis (FAP) and amezalpat for hepatocellular carcinoma (HCC), is key because it unlocks specific incentives that support higher pricing power upon approval.

The benefits associated with Orphan Drug Designation (ODD) are what you use to justify that premium price later on. These include:

• Market exclusivity upon regulatory approval.
• Tax credits for qualified clinical testing.
• Waiver or partial payment of FDA application fees.

The immediate price, frankly, is the valuation in the strategic alternatives process. Given the financial constraints, the market is pricing in the risk and potential of the pipeline today, not the future product sales. You're negotiating the value of the assets and the company structure right now.

This urgency is driven by the balance sheet. Cash position of $7.5 million as of September 30, 2025, drives the urgency for a deal. That cash level means the runway is short, so any pricing discussion must resolve before that capital is exhausted. You need to factor in the time required to close a transaction against that cash balance.